Combined therapy with co-amoxiclav and erythromycin against intracellular Legionella pneumophila in cell culture and in an experimental respiratory infection in neutropenic rats

A combination of co-amoxiclav and erythromycin has been shown in these studies to be more effective than either agent alone against intracellular Legionella pneumophila in MRC-5 cells and following oral administration in an experimental respiratory infection in neutropenic rats,